Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38654784 | 1.00 | MAPT (0.55) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL76691 | 0.89 | PRMT1 (0.46) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL1697905 | 0.85 | RAB9A (0.61) | MAPTALDH1A1HPGDSMN1; SMN2RAB9A | |
| SCHEMBL7448057 | 0.85 | ALDH1A1 (0.48) | MAPTALDH1A1HTTHPGDSMN1; SMN2 | |
| SCHEMBL396839 | 0.84 | MAPK1 (0.47) | MAPTALDH1A1HTTSMN1; SMN2RAB9A | |
| SCHEMBL9116516 | 0.84 | ALDH1A1 (0.47) | MAPTALDH1A1HTTHPGDSMN1; SMN2 | |
| SCHEMBL29537831 | 0.84 | LMNA (0.58) | MAPTALDH1A1HTTGAASMN1; SMN2 | |
| SCHEMBL1181428 | 0.84 | MEN1 (0.58) | MAPTALDH1A1HTTGAASMN1; SMN2 | |
| SCHEMBL22897658 | 0.84 | MAPT (0.49) | MAPTALDH1A1HTTGAASMN1; SMN2 | |
| SCHEMBL1885546 | 0.84 | LMNA (0.58) | MAPTALDH1A1HTTGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3441389-B1 | PYRAZOLE-OXAZOLIDINONE COMPOUND FOR ANTI-HEPATITIS B VIRUS | SHANGHAI ZHIMENG BIOPHARMA INC (CN) | 2021-09-08 | — | — | EP | disclosed |
| CN-109311865-B | Pyrazole-oxazolidinone compound for resisting hepatitis B virus | 上海挚盟医药科技有限公司 | 2021-08-31 | — | — | CN | disclosed |
| US-20190152963-A1 | PYRAZOLE-OXAZOLIDINONE COMPOUND FOR ANTI-HEPATITIS B VIRUS | SHANGHAI ZHIMENG BIOPHARMA, INC. (CN) | 2019-05-23 | — | — | US | disclosed |
| EP-3441389-A1 | PYRAZOLE-OXAZOLIDINONE COMPOUND FOR ANTI-HEPATITIS B VIRUS | Shanghai Zhimeng Biopharma Co., Ltd (CN) | 2019-02-13 | — | — | EP | disclosed |
| US-8129396-B2 | 2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | TELIK, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2346856-A1 | 2-[1H-BENZIMIDAZOL-2(3H)-YLIDENE]-2-(PYRIMIDIN-2-YL)ACETAMIDES AND 2-[BENZOTHIAZOL-2(3H)-YLIDENE]-2-(PYRIMIDIN-2-YL)ACETAMIDES AS KINASE INHIBITORS | Telik, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20100081653-A1 | 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | TELIK, INC. | 2010-04-01 | — | — | US | disclosed |
| WO-2010036873-A1 | 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | TELIK, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| US-7622592-B2 | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622592-B2 | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20060014822-A1 | 1,2,4-Triaminobenzene derivatives useful for treating disorders of the central nervous system | H. LUNDBECK A/S (DK) | 2006-01-19 | — | — | US | disclosed |
| EP-1581217-A1 | CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1578740-A1 | 1,2,4-TRIAMINOBENZENE DERIVATIVES USEFUL FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | H. Lundbeck A/S (DK) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004058739-A1 | 1,2,4-TRIAMINOBENZENE DERIVATIVES USEFUL FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | H. LUNDBECK A/S (DK) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004041277-A1 | CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-6605626-B2 | Benzamide inhibitors of factor Xa | ELI LILLY AND COMPANY | 2003-08-12 | — | — | US | disclosed |
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | BEIGHT DOUGLAS WADE (US) | 2002-08-29 | — | — | US | disclosed |
| US-6313122-B1 | AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS | ELI LILLY AND COMPANY | 2001-11-06 | — | — | US | disclosed |
| EP-1014962-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999000121-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152963-A1 | PYRAZOLE-OXAZOLIDINONE COMPOUND FOR ANTI-HEPATITIS B VIRUS | HAVCR2, ZC3HAV1, ZC3HAV1L | MAPT 3715/4885ALDH1A1 795/4885HTT 4728/4885 |
| US-20100081653-A1 | 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | MAP3K2, MAP4K2, MAP3K12 | MAPT 3439/4885ALDH1A1 1651/4885HTT 4114/4885 |
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | TFPI, F11, F12 | MAPT 4291/4885ALDH1A1 835/4885HTT 3857/4885 |
| US-20060014822-A1 | 1,2,4-Triaminobenzene derivatives useful for treating disorders of the central nervous system | PMP22, GRIN2B, AVPR1B | MAPT 392/4885ALDH1A1 112/4885HTT 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.